USPTO 2015–2025 USPTO PatentsView US Corporation

China Pacificarbide, Inc.

USPTO PatentsView assignee record - 17 granted patents across 0 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength.

RSS updates for this company

The verdict

According to USPTO PatentsView, China ranks #16,681 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 0 technology areas.

#16,681
of 49,997 US assignees by volume
3rd percentile
by Innovation Score (15.8/100)
1.0
avg claims per patent
-11%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16681 · US Corporation #16,681 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-UNK · INNOV-LOW · CLAIMS-SPARSE · TYPE-USCORP · VEL-DOWN · BOOK-RICH

  • GRANTS-MICRO 17 grants
  • MID-PACK #16,681/49,997
  • PHOTO-FINISH Centro de Inmunologí…
  • CPC-UNK CPC blank
  • INNOV-LOW 15.8/100
  • CLAIMS-SPARSE 1.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -11% vel
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Centro de Inmunología Molecular (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How China’s 15.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around China

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows China's Innovation Score is 15.8/100 (3rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for China?

Each dot is one of China’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). China’s own 1.0 claims/patent is at or below the 13.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

China vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 16.916.91717.1 0102030 Granted patents (volume) Avg claims / patent Centro de Inmunología Molecular - 17, 13.24Centro de Inmunol…Cerus Corporation - 17, 26.12CerusChengdu Vistar Optoelectronics Co., Ltd. - 17, 16.29Chengdu Vistar Op…Chi Hua Fitness Co., Ltd. - 17, 5.71Chi Hua FitnessChoice Spine, LLC - 17, 7.82Choice SpineChr. Hansen HMO GmbH - 17, 13.88Chr Hansen HMOChromaDex Inc. - 17, 20ChromadexCiambella Ltd. - 17, 18.71CiambellaChina Pacificarbide, Inc. - 17, 1China Pacificarbi…
China vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where China's grants concentrate

China Pacificarbide, Inc. is a focused PatentsView assignee: 0 CPC subclasses . Peak complete grant year is 2019 (8 grants) versus a trough of 1 in 2017. By volume, China sits between Centro de Inmunología Molecular and Ciambella Ltd..

China's three-year grant acceleration

China Pacificarbide, Inc. shows 7 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at China's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows China holds 17 patents at rank #16,696, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near China

By rank, the assignees closest to #16,696 in granted patent volume.

China's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

16 3rd percentile higher than 3% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 20172019202120222024 1
USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
China Pacificarbide, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 5.9%
2019 8 47.1%
2021 1 5.9%
2022 6 35.3%
2024 1 5.9%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

China Pacificarbide, Inc.'s patent record in context - here's where to go next.

  • Ranked #16,681 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare China Pacificarbide, Inc. against Centro de Inmunología Molecular, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 15.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.